drugset
drugset / Trial / NCT02018250

Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)

NCT02018250 ↗

Phase 1 Completed 32 enrolled U.S. Army Medical Research and Development Command
RandomizedParallel-groupTriple-blindOther

Summary

This clinical study will evaluate escalating dosages of MMB4 DMS to determine its safety when delivered intramuscularly (i.m.) to the anterior thigh.

Timeline

Start
2012-03-17
Primary completion
2012-10-16
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 1,1'-METHYLENEBIS(4-((HYDROXYIMINO)METHYL)-PYRIDINIUM) Small molecule 0.6 mg/kg Intramuscular
Subject 1,1'-METHYLENEBIS(4-((HYDROXYIMINO)METHYL)-PYRIDINIUM) Small molecule 0.9 mg/kg Intramuscular
Subject 1,1'-METHYLENEBIS(4-((HYDROXYIMINO)METHYL)-PYRIDINIUM) Small molecule 1.2 mg/kg Intramuscular
Subject 1,1'-METHYLENEBIS(4-((HYDROXYIMINO)METHYL)-PYRIDINIUM) Small molecule 1.5 mg/kg Intramuscular

Indications

No indication recorded.